| 3.32 -0.19 (-5.41%) | 05-22 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.45 | 1-year : | 4.91 |
| Resists | First : | 3.81 | Second : | 4.21 |
| Pivot price | 3.52 |
|||
| Supports | First : | 3.18 | Second : | 2.64 |
| MAs | MA(5) : | 3.55 |
MA(20) : | 3.57 |
| MA(100) : | 4.41  |
MA(250) : | 3.57 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 38.3 |
D(3) : | 44.2 |
| RSI | RSI(14): 40 |
|||
| 52-week | High : | 10.15 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BMRA ] has closed above bottom band by 13.1%. Bollinger Bands are 85% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.66 - 3.68 | 3.68 - 3.7 |
| Low: | 3.46 - 3.48 | 3.48 - 3.5 |
| Close: | 3.47 - 3.5 | 3.5 - 3.54 |
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Thu, 22 May 2025
New IBS Treatment Cuts Pain by 49% Without Drugs: Groundbreaking Real-Time Patient Monitoring System Launches - Stock Titan
Wed, 16 Apr 2025
Biomerica Announces 1-for-8 Reverse Stock Split To Regain Nasdaq Compliance - Nasdaq
Wed, 16 Apr 2025
Biomerica Announces Reverse Stock Split Effective April 21 - TipRanks
Wed, 16 Apr 2025
Biomerica announces reverse stock split to meet Nasdaq requirements - Investing.com
Wed, 16 Apr 2025
Biomerica's Strategic 1:8 Reverse Split Aims to Secure Nasdaq Future - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 9.7 (%) |
| Held by Institutions | 9.1 (%) |
| Shares Short | 43 (K) |
| Shares Short P.Month | 23 (K) |
| EPS | -2.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.17 |
| Profit Margin | -85.5 % |
| Operating Margin | -108.2 % |
| Return on Assets (ttm) | -36 % |
| Return on Equity (ttm) | -72.7 % |
| Qtrly Rev. Growth | 10 % |
| Gross Profit (p.s.) | 0.29 |
| Sales Per Share | 2.22 |
| EBITDA (p.s.) | -1.97 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.57 |
| PEG Ratio | 0 |
| Price to Book value | 1.55 |
| Price to Sales | 1.51 |
| Price to Cash Flow | -2.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|